Key Drivers
- Strong liquidity
- No revenue
- Cash burn
AIAI Summary
CMPS has shifted from a survival/funding story to a high-stakes FDA execution trade, with a repaired balance sheet buying runway for COMP360 approval and launch prep, but the stock now depends on near-term regulatory progress while remaining vulnerable to approval, commercialization, and dilution risk if momentum stalls.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •Cash burn
CMPS's balance sheet improved sharply with ample cash and lower leverage, but the lack of revenue, ongoing cash burn, and weak cash conversion still limit the investment case.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance forming
- •Pullback risk
CMPS has risen sharply over the last month and remains in an uptrend, but the rally is getting choppy as it holds support around $9.30-$9.40 while stalling near $10.60-$11.00, leaving it vulnerable to a short-term pullback.
Fast rise from $6.66 to $10.37 over the last month suggests short-term overbought risk
Sentiment & News
Key News Insights:
- •Regulatory progress
- •NDA submission
- •Better earnings
Compass Pathways is gaining momentum as regulatory breakthroughs, a rolling NDA submission, and a better-than-expected Q1 loss move COMP360 closer to a potential year-end launch.
The news is positive for CMPS, as it strengthens approval odds and near-term commercialization expectations
Similar Companies in Healthcare
Other companies in the same sector with AI ratings